Logo image of FLGT

FULGENT GENETICS INC (FLGT) Stock Fundamental Analysis

USA - NASDAQ:FLGT - US3596641098 - Common Stock

23.62 USD
+0.12 (+0.51%)
Last: 10/23/2025, 8:01:34 PM
23.45 USD
-0.17 (-0.72%)
After Hours: 10/23/2025, 8:01:34 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to FLGT. FLGT was compared to 101 industry peers in the Health Care Providers & Services industry. The financial health of FLGT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, FLGT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

FLGT had positive earnings in the past year.
In the past year FLGT has reported a negative cash flow from operations.
In multiple years FLGT reported negative net income over the last 5 years.
In the past 5 years FLGT always reported a positive cash flow from operatings.
FLGT Yearly Net Income VS EBIT VS OCF VS FCFFLGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

With a Return On Assets value of -4.25%, FLGT is not doing good in the industry: 65.35% of the companies in the same industry are doing better.
The Return On Equity of FLGT (-4.57%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -4.25%
ROE -4.57%
ROIC N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
FLGT Yearly ROA, ROE, ROICFLGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 40.04%, FLGT is in the better half of the industry, outperforming 69.31% of the companies in the same industry.
FLGT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for FLGT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
FLGT Yearly Profit, Operating, Gross MarginsFLGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FLGT has more shares outstanding
The number of shares outstanding for FLGT has been increased compared to 5 years ago.
The debt/assets ratio for FLGT has been reduced compared to a year ago.
FLGT Yearly Shares OutstandingFLGT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
FLGT Yearly Total Debt VS Total AssetsFLGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 6.27 indicates that FLGT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.27, FLGT belongs to the top of the industry, outperforming 88.12% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that FLGT is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.00, FLGT belongs to the best of the industry, outperforming 87.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.27
ROIC/WACCN/A
WACC8.61%
FLGT Yearly LT Debt VS Equity VS FCFFLGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 6.01 indicates that FLGT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 6.01, FLGT belongs to the best of the industry, outperforming 94.06% of the companies in the same industry.
A Quick Ratio of 6.01 indicates that FLGT has no problem at all paying its short term obligations.
FLGT's Quick ratio of 6.01 is amongst the best of the industry. FLGT outperforms 94.06% of its industry peers.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
FLGT Yearly Current Assets VS Current LiabilitesFLGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1433.33% over the past year.
Measured over the past years, FLGT shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.18% on average per year.
FLGT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.30%.
The Revenue has been growing by 54.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1433.33%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-53.33%
Revenue 1Y (TTM)4.3%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%15.17%

3.2 Future

The Earnings Per Share is expected to decrease by -41.72% on average over the next years. This is quite bad
Based on estimates for the next years, FLGT will show a quite strong growth in Revenue. The Revenue will grow by 11.14% on average per year.
EPS Next Y-172.16%
EPS Next 2Y-83.49%
EPS Next 3Y-41.72%
EPS Next 5YN/A
Revenue Next Year12.97%
Revenue Next 2Y11.77%
Revenue Next 3Y11.14%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FLGT Yearly Revenue VS EstimatesFLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
FLGT Yearly EPS VS EstimatesFLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 51.35 indicates a quite expensive valuation of FLGT.
The rest of the industry has a similar Price/Earnings ratio as FLGT.
FLGT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.67.
The Forward Price/Earnings Ratio is negative for FLGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 51.35
Fwd PE N/A
FLGT Price Earnings VS Forward Price EarningsFLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLGT Per share dataFLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A cheap valuation may be justified as FLGT's earnings are expected to decrease with -41.72% in the coming years.
PEG (NY)N/A
PEG (5Y)2.32
EPS Next 2Y-83.49%
EPS Next 3Y-41.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLGT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULGENT GENETICS INC

NASDAQ:FLGT (10/23/2025, 8:01:34 PM)

After market: 23.45 -0.17 (-0.72%)

23.62

+0.12 (+0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)11-07 2025-11-07/bmo
Inst Owners53.98%
Inst Owner Change0%
Ins Owners33.16%
Ins Owner Change-0.44%
Market Cap723.01M
Revenue(TTM)303.22M
Net Income(TTM)-51023000
Analysts80
Price Target25.84 (9.4%)
Short Float %10.34%
Short Ratio7.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)129.32%
Min EPS beat(2)121.2%
Max EPS beat(2)137.43%
EPS beat(4)4
Avg EPS beat(4)172.16%
Min EPS beat(4)121.2%
Max EPS beat(4)298.21%
EPS beat(8)7
Avg EPS beat(8)139.31%
EPS beat(12)11
Avg EPS beat(12)145.2%
EPS beat(16)15
Avg EPS beat(16)113.81%
Revenue beat(2)2
Avg Revenue beat(2)3.16%
Min Revenue beat(2)1.07%
Max Revenue beat(2)5.24%
Revenue beat(4)2
Avg Revenue beat(4)0.65%
Min Revenue beat(4)-1.93%
Max Revenue beat(4)5.24%
Revenue beat(8)5
Avg Revenue beat(8)4.41%
Revenue beat(12)9
Avg Revenue beat(12)6.22%
Revenue beat(16)12
Avg Revenue beat(16)6.53%
PT rev (1m)0%
PT rev (3m)11.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.56%
EPS NY rev (1m)22.39%
EPS NY rev (3m)36.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.04%
Valuation
Industry RankSector Rank
PE 51.35
Fwd PE N/A
P/S 2.38
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)0.46
EY1.95%
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS9.91
BVpS36.48
TBVpS31.48
PEG (NY)N/A
PEG (5Y)2.32
Graham Number19.43
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -4.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.04%
FCFM N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.73%
Cap/Sales 11.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z 6.27
F-Score6
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)101.39%
Cap/Depr(5y)338.11%
Cap/Sales(3y)8.31%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1433.33%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-53.33%
EPS Next Y-172.16%
EPS Next 2Y-83.49%
EPS Next 3Y-41.72%
EPS Next 5YN/A
Revenue 1Y (TTM)4.3%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%15.17%
Revenue Next Year12.97%
Revenue Next 2Y11.77%
Revenue Next 3Y11.14%
Revenue Next 5YN/A
EBIT growth 1Y-1.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.88%
EBIT Next 3Y23.19%
EBIT Next 5YN/A
FCF growth 1Y-290.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-144.97%
OCF growth 3Y-66.06%
OCF growth 5Y30.8%